Soma Pharmacy Blognews

Alliance Pharma To Acquire Cambridge Laboratories

Posted by: SomaNews on: 09 Feb, 2010

Alliance Pharma To Acquire Cambridge Laboratories

Alliance Pharma has conditionally agreed to acquire Cambridge Laboratories (Ireland) and Cambridge Laboratories (together the ‘Vendors’), for total consideration of between £14.3m and £16.4m, plus the value of inventory held by the Vendors at completion. The acquisition is expected to be completed on 22 February, 2010.

Merz Launches Denzapine In Ireland

Posted by: SomaNews on: 09 Feb, 2010

Merz Launches Denzapine In Ireland

Merz Pharma (Merz) has launched Denzapine, generic version of Clozapine in Ireland. Clozapine is an antipsychotic medication. The product is available in the UK since February 2004, reported medical news today.

Hospitals selling uninsured drugs may negatively impact public system

Governments are under increasing pressure to provide access to expensive new drugs. Canadian patients who want access to drugs that are not publicly insured are seeking to pay for these drugs within public hospitals, states an article in CMAJ (Canadian Medical Association Journal) (pre-embargo link only).

FDA approves Amneal Pharmaceuticals’ Tramadol/APAP tablets

Amneal Pharmaceuticals is pleased to announce that it received U.S. FDA approval to manufacture combination Tramadol HCl in 37.5 mg strength and Acetaminophen in 325 mg strength (Tramadol/APAP) in tablet form effective December 9, 2009. Amneal’s generic is an AB-rated, therapeutically equivalent alternative to Ultracet® (a licensed trademark of Ortho-McNeil Janssen). U.S. sales of Tramadol/APAP were $61 MM according to June 2009 IMS Health market data.

Repros Therapeutics submits Androxal revised indication statement to the FDA

Repros Therapeutics Inc. today announced that the Company, as requested by the FDA during the Type C meeting held on January 25, 2010, has sent a revised indication statement to the FDA’s Division of Reproductive and Urologic Products for the use of Androxal® in the treatment of men wishing to preserve fertility while being treated for their hypogonadal state.

3SBio announces Nephoxil collaboration and license agreement with Panacor Bioscience

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced a collaboration and license agreement with Panacor Bioscience Ltd. to develop and commercialize its Nephoxil(R) pharmaceutical product for the treatment of hyperphosphatemia in China.

LPC Pharma Group outsources pharmacovigilance/drug safety operations to APCER Pharma

APCER Pharma announced that LPC Pharma Group is outsourcing its pharmacovigilance/drug safety operations to APCER.

Novavax to discontinue collaboration agreement with ROVI Pharmaceuticals

Novavax, Inc. announced today that the company has decided to discontinue negotiations in its pursuit of the previously announced collaboration with ROVI Pharmaceuticals to develop Novavax’s virus-like-particle (VLP)-based vaccines against influenza in the country of Spain.

Researchers find low prevalence of tamoxifen use for prevention of breast cancer among women

Researchers with the National Cancer Institute (NCI) have found that the prevalence of tamoxifen use for the prevention of breast cancer among women without a personal history of breast cancer is very low.

Investigational drug for osteoporosis inhibits serotonin synthesis in the gut

An investigational drug that inhibits serotonin synthesis in the gut, administered orally once daily, effectively cured osteoporosis in mice and rats reports an international team led by researchers from Columbia University Medical Center, in the Feb. 7 issue of Nature Medicine.

Categories

soma
ambien
duty free tobacco
Rolex Replica

Archives

 

February 2010
M T W T F S S
« Jan    
1234567
891011121314
15161718192021
22232425262728